BG Medicine Inc
BG Medicine, Inc., a diagnostics company, engages in the development and commercialization of novel cardiovascular diagnostic tests to address unmet medical needs in the United States, Europe, and internationally. It offers BGM Galectin-3 test, a novel diagnostic test that measures galectin-3 in blood plasma or serum; and CardioSCORE test that is designed to identify cardiovascular events, such a… Read more
BG Medicine Inc (BGMD) - Net Assets
Latest net assets as of December 2015: $-1.98 Million USD
Based on the latest financial reports, BG Medicine Inc (BGMD) has net assets worth $-1.98 Million USD as of December 2015.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.13 Million) and total liabilities ($4.11 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-1.98 Million |
| % of Total Assets | -92.64% |
| Annual Growth Rate | N/A |
| 5-Year Change | -109.46% |
| 10-Year Change | N/A |
| Growth Volatility | 165.9 |
BG Medicine Inc - Net Assets Trend (2004–2015)
This chart illustrates how BG Medicine Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for BG Medicine Inc (2004–2015)
The table below shows the annual net assets of BG Medicine Inc from 2004 to 2015.
| Year | Net Assets | Change |
|---|---|---|
| 2015-12-31 | $-1.98 Million | -454.76% |
| 2014-12-31 | $557.00K | +152.10% |
| 2013-12-31 | $-1.07 Million | -445.95% |
| 2012-12-31 | $309.00K | -98.52% |
| 2011-12-31 | $20.89 Million | +126.99% |
| 2010-12-31 | $-77.41 Million | -21.14% |
| 2009-12-31 | $-63.90 Million | -29.98% |
| 2008-12-31 | $-49.16 Million | -51.35% |
| 2006-12-31 | $-32.48 Million | -14.57% |
| 2005-12-31 | $-28.35 Million | -24.82% |
| 2004-12-31 | $-22.72 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to BG Medicine Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 13609300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2015)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $11.00K | % |
| Other Comprehensive Income | $-2.59 Million | % |
| Other Components | $166.91 Million | % |
| Total Equity | $-1.98 Million | 100.00% |
BG Medicine Inc Competitors by Market Cap
The table below lists competitors of BG Medicine Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Arctic Textile
KAR:ARCTM
|
$831.20 |
|
CHU KONG SHIPPING
BE:CKW
|
$833.12 |
|
Drummond Ventures Corp.
V:DVX-P
|
$833.26 |
|
Alfi Inc.
PINK:ALFIQ
|
$833.41 |
|
PV2 Investment JSC
VN:PV2
|
$829.37 |
|
Mirpurkhas Sugar Mills Ltd
KAR:MIRKS
|
$828.41 |
|
PARADIGM METALS
BE:P1G
|
$827.87 |
|
TROPICAL PARADISE CO. LTD (ORDINARY)
SEM:TPL-O
|
$827.70 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BG Medicine Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2014 to 2015, total equity changed from 557,000 to -1,976,000, a change of -2,533,000 (-454.8%).
- Net loss of 5,303,000 reduced equity.
- Dividend payments of 2,500,000 reduced retained earnings.
- Share repurchases of 456,000 reduced equity.
- Other comprehensive income decreased equity by 2,594,000.
- Other factors increased equity by 8,320,000.
Equity Change Factors (2014 to 2015)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-5.30 Million | -268.37% |
| Dividends Paid | $2.50 Million | -126.52% |
| Share Repurchases | $456.00K | -23.08% |
| Other Comprehensive Income | $-2.59 Million | -131.28% |
| Other Changes | $8.32 Million | +421.05% |
| Total Change | $- | -454.76% |
Book Value vs Market Value Analysis
This analysis compares BG Medicine Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | $-30.58 | $0.00 | x |
| 2005-12-31 | $-38.17 | $0.00 | x |
| 2006-12-31 | $-43.73 | $0.00 | x |
| 2008-12-31 | $-66.18 | $0.00 | x |
| 2009-12-31 | $-87.21 | $0.00 | x |
| 2010-12-31 | $-104.20 | $0.00 | x |
| 2011-12-31 | $4.74 | $0.00 | x |
| 2012-12-31 | $0.06 | $0.00 | x |
| 2013-12-31 | $-0.16 | $0.00 | x |
| 2014-12-31 | $0.07 | $0.00 | x |
| 2015-12-31 | $-0.21 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BG Medicine Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -338.63%
- • Asset Turnover: 0.73x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-838.56%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2004 | 0.00% | -102.50% | 0.38x | 0.00x | $-311.40K |
| 2005 | 0.00% | -537.34% | 0.49x | 0.00x | $-5.40 Million |
| 2006 | 0.00% | -78.43% | 0.98x | 0.00x | $-1.49 Million |
| 2008 | 0.00% | -103.39% | 0.41x | 0.00x | $-10.16 Million |
| 2009 | 0.00% | -190.07% | 0.67x | 0.00x | $-9.75 Million |
| 2010 | 0.00% | -2095.48% | 0.12x | 0.00x | $-9.42 Million |
| 2011 | -84.16% | -1076.01% | 0.06x | 1.25x | $-19.67 Million |
| 2012 | -7692.23% | -844.37% | 0.18x | 49.32x | $-23.80 Million |
| 2013 | 0.00% | -389.12% | 0.44x | 0.00x | $-15.74 Million |
| 2014 | -1447.76% | -289.34% | 0.53x | 9.39x | $-8.12 Million |
| 2015 | 0.00% | -338.63% | 0.73x | 0.00x | $-5.11 Million |
Industry Comparison
This section compares BG Medicine Inc's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,683,526,542
- Average return on equity (ROE) among peers: -32.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BG Medicine Inc (BGMD) | $-1.98 Million | 0.00% | N/A | $831.08 |
| ANGELALIGN TECHNOLOGY INC (AGLFF) | $480.24 Million | 2.52% | 0.41x | $405.57 Million |
| Akoya Biosciences Inc (AKYA) | $-30.16 Million | 0.00% | 0.00x | $16.24 Million |
| Alcon AG (ALC) | $19.68 Billion | 1.70% | 0.48x | $37.82 Billion |
| Align Technology Inc (ALGN) | $3.85 Billion | 10.94% | 0.61x | $11.75 Billion |
| AngioDynamics Inc (ANGO) | $355.71 Million | 3.06% | 0.15x | $354.40 Million |
| Ansell Limited (ANSLF) | $386.33 Million | -0.45% | 0.87x | $2.58 Billion |
| AptarGroup Inc (ATR) | $2.07 Billion | 11.57% | 1.03x | $8.27 Billion |
| AtriCure Inc (ATRC) | $72.60 Million | -15.79% | 0.54x | $1.42 Billion |
| Avinger Inc (AVGR) | $-35.69 Million | 0.00% | 0.00x | $1.26 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $9.03 Million | -338.35% | 0.77x | $156.14 Million |